GlassScriptPhysician profile
Kelli B Arthur
NPI 1508284522
$1,344.64
in general payments reported to CMS, 2019-2025
29 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2023: $39.16 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.07 | 2023-2025 | |
| Novo Nordisk INC | $141.79 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $141.14 | 2025 | Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.20 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $57.75 | 2025 | Auvelity |
| Lilly USA, LLC | $55.69 | 2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $47.03 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $46.07 | 2025 | Rexulti |
| Ardelyx, INC. | $45.17 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.86 | 2025 | Jardiance, Ofev |
| Pfizer INC. | $40.35 | 2025 | |
| Amneal Pharmaceuticals LLC | $38.69 | 2025 | Unithroid |
| Exact Sciences Corporation | $36.77 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $36.70 | 2025 | Fanapt |
| Lundbeck LLC | $31.73 | 2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rgh Enterprises LLC | $25.78 | 2025 | |
| Harmony Biosciences LLC | $23.45 | 2025 | |
| Boston Scientific Corporation | $22.70 | 2025 | Watchman Flx |
| Edwards Lifesciences Corporation | $22.50 | 2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $20.95 | 2025 | |
| Sumitomo Pharma America, INC. | $19.62 | 2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $19.12 | 2025 | Edarbi |
| Supernus Pharmaceuticals, INC. | $18.71 | 2021 | |
| Aimmune Therapeutics, INC. | $17.72 | 2025 | Vowst |
| Glaxosmithkline, LLC. | $16.53 | 2025 | Trelegy Ellipta |
| Dexcom, INC. | $15.61 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $14.18 | 2025 | Freestyle Libre 3 |
| Corium, LLC | $11.08 | 2023 | Azstarys |
| Phathom Pharmaceuticals, INC. | $8.68 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.